Ironwood Pharma (IRWD) Misses Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall St mixed as Middle East tensions eclipse tech strength
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Ironwood Pharmaceuticals Provides Second Quarter 2016 Investor Update
August 4, 2016 4:10 PM EDTIronwood revenue increased 96% to $54.4 million in 2Q 2016 compared to 2Q 2015
LINZESS® (linaclotide) U.S. net sales increased 34% to $150.5 million in 2Q 2016 over 2Q 2015; net profit for the brand increased to $58 million from $15 million
On track to launch two priority franchise products: ZURAMPIC® (lesinurad) in October 2016 for hyperuricemia associated with uncontrolled gout and 72 mcg linaclotide in early 2017 for chronic idiopathic constipation
CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More
